Search Results - "Craxi', A"

Comparison of Transient Elastography and Acoustic Radiation Force Impulse for Non-Invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C by RIZZO, L, CALVARUSO, Vincenza, NUNNARI, G, BRONTE, F, DI MARCO, V, CRAXI, A, CAMMA, C, CACOPARDO, B, ALESSI, N, ATTANASIO, M, PETTA, S, FATUZZO, F, MONTINERI, A, MAZZOLA, A, L'ABBATE, L

“…Transient elastography (TE) is adequate for a diagnosis of cirrhosis, but its accuracy for milder stages of fibrosis is much less satisfactory. The objective…”
Get full text

Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD by Petta, S., Wong, V. W.‐S., Cammà, C., Hiriart, J.‐B., Wong, G. L.‐H., Vergniol, J., Chan, A. W.‐H., Di Marco, V., Merrouche, W., Chan, H. L.‐Y., Marra, F., Le‐Bail, B., Arena, U., Craxì, A., Ledinghen, V.

“…Summary Background The accuracy of available non‐invasive tools for staging severe fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) is still…”
Get full text

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver by Dongiovanni, P., Stender, S., Pietrelli, A., Mancina, R. M., Cespiati, A., Petta, S., Pelusi, S., Pingitore, P., Badiali, S., Maggioni, M., Mannisto, V., Grimaudo, S., Pipitone, R. M., Pihlajamaki, J., Craxi, A., Taube, M., Carlsson, L. M.S., Fargion, S., Romeo, S., Kozlitina, J., Valenti, L.

“…Background and Aims Nonalcoholic fatty liver disease is epidemiologically associated with hepatic and metabolic disorders. The aim of this study was to examine…”
Get full text

Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease by Petta, S., Amato, M. C., Di Marco, V., Cammà, C., Pizzolanti, G., Barcellona, M. R., Cabibi, D., Galluzzo, A., Sinagra, D., Giordano, C., Craxì, A.

“…Aliment Pharmacol Ther 2012; 35: 238–247 Summary Background  Metabolic factors have been associated with liver damage in patients with non‐alcoholic fatty…”
Get full text

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study by Cabibbo, G., Petta, S., Calvaruso, V., Cacciola, I., Cannavò, M. R., Madonia, S., Distefano, M., Larocca, L., Prestileo, T., Tinè, F., Bertino, G., Giannitrapani, L., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Cartabellotta, F., Alessi, N., Barbàra, M., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Craxì, A., Di Marco, V., Cammà, C., Craxì, A., Di Marco, V., Cammà, C., Calvaruso, V., Petta, S., Colletti, P., Mazzola, G., Licata, A., Giannitrapani, L., Corrao, S., Prestileo, T., Di Lorenzo, F., Fecarotta, R., Sanfilippo, P., Madonia, S., Tinè, F., Malizia, G., Latteri, F., Maida, M., Cartabellotta, F., Vassallo, R., Cacciola, I., Caccamo, G., Maimone, S., Saitta, C., Squadrito, G., Raimondo, G., Mondello, L., Smedile, A., Bertino, G., Ardiri, A.L., Montineri, A., Larocca, L. N., Cacopardo, B., Benanti, F., Russello, M., Benigno, R., Cannavò, M. R., Bellia, A., Iacobello, C., Davì, A., Di Rosolini, M. A., Digiacomo, A., Fuduli, G., Scifo, G., Distefano, M., Portelli, V., Savalli, F., Scalici, I., Gioia, G., Magro, A., Alaimo, G., Salvo, A., Averna, A., Lomonaco, F., Quattrocchi, U., Guarneri, L., Maffeo, F.

“…Summary Background Data on HCV‐related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by…”
Get full text

Boceprevir for Untreated Chronic HCV Genotype 1 Infection by Poordad, Fred, McCone, Jonathan, Bacon, Bruce R, Bruno, Savino, Manns, Michael P, Sulkowski, Mark S, Jacobson, Ira M, Reddy, K. Rajender, Goodman, Zachary D, Boparai, Navdeep, DiNubile, Mark J, Sniukiene, Vilma, Brass, Clifford A, Albrecht, Janice K, Bronowicki, Jean-Pierre

“…In this trial involving previously untreated patients infected with hepatitis C virus (HCV) genotype 1, boceprevir in combination with peginterferon and…”
Get full text

Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe by Papatheodoridis, G. V., Hatzakis, A., Cholongitas, E., Baptista‐Leite, R., Baskozos, I., Chhatwal, J., Colombo, M., Cortez‐Pinto, H., Craxi, A., Goldberg, D., Gore, C., Kautz, A., Lazarus, J. V., Mendão, L., Peck‐Radosavljevic, M., Razavi, H., Schatz, E., Tözün, N., Damme, P., Wedemeyer, H., Yazdanpanah, Y., Zuure, F., Manns, M. P.

“…Summary Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically…”
Get full text

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon by Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Tovoli, F., Ciccarese, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Virdone, R., Marra, F., Felder, M., Morisco, F., Benvegnù, L., Gasbarrini, A., Svegliati‐Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Nardone, G., Colecchia, A., Persico, M., Boccaccio, V., Craxì, A., Bruno, S., Trevisani, F., Cammà, C., Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Piscaglia, Fabio, Gramenzi, Annagiulia, Granito, Alessandro, Magalotti, Donatella, Serra, Carla, Negrini, Giulia, Napoli, L., Napoli, Lucia, Salvatore, Veronica, Benevento, Francesca, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Poggio, Paolo Del, Olmi, Stefano, Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, Dell'Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Rini, Francesca, Costantino, Andrea, Affronti, Andrea, Affronti, Marco, Mascari, Marta, Mega, Andrea, Pompili, Maurizio, Rinninella, Emanuele, Mismas, Valeria, Dall'Aglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Missale, Gabriele, Guarino, Maria, Ortolani, Alessio, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Aburas, Sami, Inghilesi, Andrea L., Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Coccoli, Piero, Zamparelli, Marco Sanduzzi

“…Summary Background In HCV‐infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the…”
Get full text

Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems by CAMMÀ, C., MARCO, V. DI, CABIBBO, G., LATTERI, F., SANDONATO, L., PARISI, P., ENEA, M., ATTANASIO, M., GALIA, M., ALESSI, N., LICATA, A., LATTERI, M. A., CRAXÌ, A.

“…Summary Background  A major problem in assessing the likelihood of survival of patients with hepatocellular carcinoma (HCC) arises from a lack of models…”
Get full text

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis by Di Marco, V., Covolo, L., Calvaruso, V., Levrero, M., Puoti, M., Suter, F., Gaeta, G. B., Ferrari, C., Raimondo, G., Fattovich, G., Santantonio, T., Alberti, A., Bruno, R., Mussini, C., Mondelli, M., Donato, F., Craxì, A.

“…Summary We assessed, in real‐life practice, viral, demographic, genetic and metabolic factors influencing the sustained virologic response (SVR), with a…”
Get full text

Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy by Calvaruso, V., Cammà, C., Di Marco, V., Maimone, S., Bronte, F., Enea, M., Dardanoni, V., Manousou, P., Pleguezuelo, M., Xirouchakis, E., Attanasio, M., Dusheiko, G., Burroughs, A. K., Craxì, A.

“…In chronic hepatitis C, transient elastography (TE) accurately identifies cirrhosis, but its ability to assess significant fibrosis (Metavir ≥ F2) is variable…”
Get full text

Add-On Peginterferon Alfa-2a Significantly Reduces HBsAg Levels in HBeAg-Negative, Genotype D Chronic Hepatitis B Patients Fully Suppressed on Nucleot(s)ide Analogues Treatment: Final Results of the Hermes Study by Lampertico, P, Brunetto, M.R, Craxi, A, Gaeta, G.B, Rizzetto, M, Rozzi, A, Colombo, M

Get full text

Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease by Petta, S., Ciminnisi, S., Di Marco, V., Cabibi, D., Cammà, C., Licata, A., Marchesini, G., Craxì, A.

“…Summary Background Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including…”
Get full text

IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection by O'Connor, K S, Read, S A, Wang, M, Schibeci, S, Eslam, M, Ong, A, Weltman, M D, Douglas, M W, Mazzola, A, Craxì, A, Petta, S, Stewart, G J, Liddle, C, George, J, Ahlenstiel, G, Booth, D R

“…Single-nucleotide polymorphisms near the interferon lambda 3 ( IFNL3 ) gene predict outcomes to infection and anti-viral treatment in hepatitis C virus (HCV)…”
Get full text

Oral pathology in untreated coelic disease by CAMPISI, G., DI LIBERTO, C., IACONO, G., COMPILATO, D., DI PRIMA, L., CALVINO, F., DI MARCO, V., LO MUZIO, L., SFERRAZZA, C., SCALICI, C., CRAXÌ, A., CARROCCIO, A.

“…Summary Background  Many coeliac disease patients with atypical symptoms remain undiagnosed. Aim  To examine the frequency of oral lesions in coeliac disease…”
Get full text

Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? by Schepis, Filippo, Cammà, Calogero, Niceforo, Domenico, Magnano, Antonio, Pallio, Socrate, Cinquegrani, Maurizio, D'Amico, Gennaro, Pasta, Linda, Craxı̀, Antonio, Saitta, Antonino, Raimondo, Giovanni

“…Our aims were to develop a noninvasive predictive tool to identify cirrhotic patients with esophageal varices and to evaluate whether portal Doppler…”
Get full text

Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir without Ribavirin in Patients with HCV Genotype 1b with or without Compensated Cirrhosis: Pooled Analysis across 5 Clinical Trials by Welzel, T.M, Isakov, V, Trinh, R, Streinu-Cercel, A, Dufour, J.-F, Marinho, R.T, Moreno, C, Liu, L, Xie, W, Tatsch, F, Shulman, N, Craxi, A

Get full text

Non-alcoholic fatty liver disease pathogenesis: The present and the future by Petta, S, Muratore, C, Craxì, A

“…Abstract Non-alcoholic fatty liver disease is the clinical hepatic expression of metabolic syndrome. The prevalence of non-alcoholic fatty liver disease is…”
Get full text

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program by Bruno, S., Bollani, S., Zignego, A. L., Pascasio, J. M., Magni, C., Ciancio, A., Caremani, M., Mangia, A., Marenco, S., Piovesan, S., Chemello, L., Babudieri, S., Moretti, A., Gea, F., Colletta, C., Perez-Alvarez, R., Forns, X., Larrubia, J. R., Arenas, J., Crespo, J., Calvaruso, V., Ceccherini Silberstein, F., Maisonneuve, P., Craxì, A., Calleja, J. L.

“…Summary In many countries, first‐generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV‐infected…”
Get full text

P.07.4 HEMOGLOBIN AND FERRITIN VALUES ARE ASSOCIATED WITH INCREASED RATE OF MUCOSAL HEALING IN PATIENTS WITH CROHN'S DISEASE TREATED WITH ANTI-TNF ALPHA by Mendolaro, M, Cappello, M, Viola, A, Cilluffo, M.G, Vita, G, Peralta, S, Calvaruso, V, Craxi, A

Get full text